摘要
非小细胞肺癌(NSCLC)脑转移是一种预后较差的疾病,手术与非手术方式已用于治疗NSCLC脑转移,文中对手术和其他方案治疗NSCLC脑转移的疗效研究进展作综述。
Non-small cell lung cancer( NSCLC) with brain metastasis is a disease with poor prognosis. Surgery and non-surgical methods have been used to treat NSCLC with brain metastasis. This review compared surgery with other methods in the treatment of NSCLC with brain metastasis.
引文
[1]Seoane J,De Mattos-Arruda L.Brain metastasis:new opportunities to tackle therapeutic resistance[J].Mol Oncol,2014,8:1120-1131
[2]Berger LA,Riesenberg H,Bokemeyer C,et al.CNS metastases in non-small-cell lung cancer:current role of EGFR-TKI therapy and future perspectives[J].Lung Cancer,2013,80:242-248
[3]Andrews,DW,Scott CB,Sperduto PW,et al.Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases:phase III results of the RTOG 9508 randomised trial[J].Lancet,2004,363:1665-1672
[4]Moscetti L,Nelli F,Felici A,et al.Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases:survey by Outcome Research Network for Evaluation of Treatment Results in Oncology[J].Cancer,2007,109:274-281
[5]Postmus PE,Smit EF.Chemotherapy for brain metastases of lung cancer:a review[J].Ann Oncol,1999,10:753-759
[6]欧阳汉,周纯武,张红梅.肺癌脑转移的MRI特点[J].中华肿瘤杂志,2004,26:315-318
[7]Li B,Wang C,Zhang Y,et al.Elevated PLGF contributes to small-cell lung cancer brain metastasis[J].Oncogene,2013,32:2952-2962
[8]Yang P,Allen MS,Aubry MC,et al.Clinical features of 5,628primary lung cancer patients:experience at Mayo Clinic from1997 to 2003[J].Chest,2005,128:452-462
[9]徐健,周范民,王宇倩,CD44v6在脑转移癌中的表达[J].中国临床神经科学,2001,9:234-236
[10]Rockoff MA.Stereotactic radiosurgery for the management of brain metastases[J].N Engl J Med,2010,363:592
[11]Muacevic A,Kreth FW,Horstmann GA,et al.Surgery and radiotherapy compared with gamma knife radiosurgery in the treatment of solitary cerebral metastases of small diameter[J].JNeurosurg,1999,91:35-43
[12]Patchell RA,Tibbs PA,Walsh JW,et al.A randomized trial of surgery in the treatment of single metastases to the brain[J].NEngl J Med,1990,322:494-500
[13]Vecht CJ,Haaxma-Reiche H,Noordijk EM,et al.Treatment of single brain metastasis:radiotherapy alone or combined with neurosurgery?[J].Ann Neurol,1993,33:583-590
[14]Mintz AH,Kestle J,Rathbone MP,et al.A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis[J].Cancer,1996,78:1470-1476
[15]Roberge D,Petrecca K,El Refae M,et al.Whole-brain radiotherapy and tumor bed radiosurgery following resection of solitary brain metastases[J].J Neurooncol,2009,95:95-99
[16]Patchell RA,Tibbs PA,Regine WF,et al.Postoperative radiotherapy in the treatment of single metastases to the brain:a randomized trial[J].JAMA,1998,280:1485-1489
[17]Tsao MN,Rades D,Wirth A,et al.Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es):An American Society for Radiation Oncology evidence-based guideline[J].Pract Radiat Oncol,2012,2:210-225
[18]Patel KR,Prabhu RS,Kandula S,et al.Intracranial control and radiographic changes with adjuvant radiation therapy for resected brain metastases:whole brain radiotherapy versus stereotactic radiosurgery alone[J].J Neurooncol,2014,120:657-663
[19]Brown PD,Ballman KV,Cerhan JH,et al.Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease(NCCTG N107C/CEC.3):a multicentre,randomised,controlled,phase 3 trial[J].Lancet Oncol,2017,18:1049-1060
[20]Tian LJ,Zhuang HQ,Yuan ZY.A comparison between cyberknife and neurosurgery in solitary brain metastases from nonsmall cell lung cancer[J].Clin Neurol Neurosurg,2013,115:2009-2014
[21]Hu C,Chang EL,Hassenbusch SJ 3rd,et al.Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis[J].Cancer,2006,106:1998-2004
[22]Bai H,Han B.Surgical treatment for non-small cell lung cancer patients with synchronous solitary brain metastasis[J].Zhongguo Fei Ai Za Zhi,2013,16:646-650
[23]Weil RJ,Mavinkurve GG,Chao ST,et al.Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis:initial experience and long-term outcomes[J].J Neurosurg,2015,122:825-832
[24]Parlak C,Mertsoylu H2,Güler OC,et al.Definitive chemoradiation therapy following surgical resection or radiosurgery plus whole-brain radiation therapy in non-small cell lung cancer patients with synchronous solitary brain metastasis:a curative approach[J].Int J Radiat Oncol Biol Phys,2014,88:885-891
[25]Downey RJ,Ng KK,Kris MG,et al.A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis[J].Lung Cancer,2002,38:193-197
[26]Bogart JA,Ungureanu C,Shihadeh E,et al.Resection and permanent I-125 brachytherapy without whole brain irradiation for solitary brain metastasis from non-small cell lung carcinoma[J].J Neurooncol,1999,44:53-57
[27]Flannery TW,Suntharalingam M,Regine WF,et al.Long-term survival in patients with synchronous,solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery[J].Int J Radiat Oncol Biol Phys,2008,72:19-23
[28]Gui Q,Liu J,Li D,et al.Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs[J].World J Surg Oncol,2017,15:184
[29]Lischalk JW,Oermann E,Collins SP,et al.Five-fraction stereotactic radiosurgery(SRS)for single inoperable high-risk non-small cell lung cancer(NSCLC)brain metastases[J].Radiat Oncol,2015,10:216
[30]Putora PM,Ess S,Panje C,Hundsberger T,et al.Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer(NSCLC)[J].Clin Exp Metastasis,2015,32:143-149
[31]Kress MA,Oermann E,Ewend MG,et al.Stereotactic radiosurgery for single brain metastases from non-small cell lung cancer:progression of extracranial disease correlates with distant intracranial failure[J].Radiat Onco,2013,8:64
[32]I H,Lee JI,Nam DH,et al.Surgical treatment of non-small cell lung cancer with isolated synchronous brain metastases[J].JKorean Med Sci,2006,21:236-241
[33]Daniels M,Wright GM.Complete resection of non-small-cell lung cancer and oligo-metastatic brain disease[J].ANZ J Surg,2005,75:963-966
[34]Getman V,Devyatko E,Dunkler D,et al.Prognosis of patients with non-small cell lung cancer with isolated brain metastases undergoing combined surgical treatment[J].Eur J Cardiothorac Surg,2004,25:1107-1113
[35]Flannery TW,Suntharalingam M,Kwok Y,et al.Gamma knife stereotactic radiosurgery for synchronous versus metachronous solitary brain metastases from non-small cell lung cancer[J].Lung Cancer,2003,42:327-333
[36]Koutras AK,Marangos M,Kourelis T,et al.Surgical management of cerebral metastases from non-small cell lung cancer[J].Tumori,2003,89:292-297
[37]Granone P,Margaritora S,D'Andrilli A,et al.Non-small cell lung cancer with single brain metastasis:the role of surgical treatment[J].Eur J Cardiothorac Surg,2001,20:361-366
[38]Bai H,Han BH.Role of surgical resection in comprehensive treatment for patients with non-small cell lung cancer and solitary brain metastasis[J].Journal of Shanghai Jiaotong University(Medical Science),2011,31:309-312
[39]Kondziolka D,Patel A,Lunsford LD,et al.Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases[J].Int J Radiat Oncol Biol Phys,1999,45:427-434
[40]Andrews DW,Scott CB,Sperduto PW,et al.Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases:phase III results of the RTOG 9508 randomised trial[J].Lancet,2004,363:1665-1672
[41]Soon YY,Tham IW,Lim KH,et al.Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases[J].Cochrane Database Syst Rev,2014,(3):CD009454
[42]Aoyama H,Shirato H,Tago M,et al.Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases:a randomized controlled trial[J].JAMA,2006,295:2483-2491
[43]Chang EL,Wefel JS,Hess KR,et al.Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation:a randomised controlled trial[J].Lancet Oncol,2009,10:1037-1044
[44]Paul Brown,Anthony Asher,Karla Ballman,et al.NCCTGN0574(Alliance):A phase III randomized trial of whole brain radiation therapy(WBRT)in addition to radiosurgery(SRS)in patients with 1 to 3 brain metastases[J].Neuro Oncol,2015,33:45-46
[45]Churilla TM,Handorf E1,Collette S,et al.Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses:a secondary analysis of EORTC 22952-26001[J].Ann Oncol,2017,28:2588-2594
[46]Sahgal A,Aoyama H,Kocher M,et al.Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases:individual patient data metaanalysis[J].Int J Radiat Oncol Biol Phys,2015,91:710-717
[47]Aoyama H,Tago M,Shirato H,et al.Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases:Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial[J].JAMA Oncol,2015,1:457-464
[48]Syrigos KN,Georgoulias V,Zarogoulidis K,et al.Epidemiological Characteristics,EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients:The Greek REASON Observational Registry Study[J].Anticancer Res,2018,38:3735-3744
[49]Huttenlocher S,Dziggel L,Hornung D,et al.A new prognostic instrument to predict the probability of developing new cerebral metastases after radiosurgery alone[J].Radiat Oncol,2014,9:215
[50]Patil CG,Pricola K,Sarmiento JM,et al.Whole brain radiation therapy(WBRT)alone versus WBRT and radiosurgery for the treatment of brain metastases[J].Cochrane Database Syst Rev,2017,9:CD006121
[51]Tsao MN,Xu W,Wong RK,et al.Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases[J].Cochrane Database Syst Rev,2018,1:CD003869
[52]Mulvenna P,Nankivell M,Barton R,et al.Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy(QUARTZ):results from a phase 3,non-inferiority,randomised trial[J].Lancet,2016,388:2004-2014
[53]Cancer Genome Atlas Research Network.Comprehensive molecular profiling of lung adenocarcinoma[J].Nature,2014,511:543-550
[54]Ladanyi M,Pao W.Lung adenocarcinoma:guiding EGFR-targeted therapy and beyond[J].Mod Pathol,2008,21 Suppl 2:S16-22
[55]Jackman DM,Holmes AJ,Lindeman N,et al.Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib[J].J Clin Oncol,2006,24:4517-4520
[56]Wu YL,Yang JJ,Zhou C,et al.PL03.05:BRAIN:A Phase III Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations(CTONG 1201)[J].J Thorac Oncol,2017,12:S6.
[57]Hoffknecht P,Tufman A,Wehler T,et al.Efficacy of the irreversible Erb B family blocker afatinib in epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor(TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease[J].J Thorac Oncol,2015,10:156-163
[58]Mok TSK,Kim SW,Wu YL,et al.Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib(IMPRESS):Overall Survival and Biomarker Analyses[J].J Clin Oncol,2017,35:4027-4034
[59]Putora PM,Ess S,Panje C,et al.Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer(NSCLC)[J].Clin Exp Metastasis,2015,32:143-149
[60]Soria JC,Ohe Y,Vansteenkiste J,et al.Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J].N Engl J Med,2018,378:113-125
[61]Morris SW,Kirstein MN,Valentine MB,et al.Fusion of a kinase gene,ALK,to a nucleolar protein gene,NPM,in nonHodgkin's lymphoma[J].Science,1994,263:1281-1284
[62]Iwahara T,Fujimoto J,Wen D,et al.Molecular characterization of ALK,a receptor tyrosine kinase expressed specifically in the nervous system[J].Oncogene,1997,14:439-449
[63]Jnne PA,Shaw AT,Camidge DR,et al.Combined Pan-HERand ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer:Results of a Phase IStudy[J].J Thorac Oncol,2016,11:737-747
[64]Vernersson E,Khoo NK,Henriksson M,et al.Characterization of the expression of the ALK receptor tyrosine kinase in mice[J].Gene Expr Patterns,2006,6:448-461
[65]Bilsland JG,Wheeldon A,Mead A,et al.Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications[J].Neuropsychopharmacology,2008,33:685-700
[66]Li YS,Milner PG,Chauhan AK,et al.Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity[J].Science,1990,250:1690-1694
[67]Guan J,Umapathy G,Yamazaki Y,et al.FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase[J].Elife,2015,4:e09811
[68]Reshetnyak AV,Murray PB,Shi X,et al.Augmentorαandβ(FAM150)are ligands of the receptor tyrosine kinases ALK and LTK:Hierarchy and specificity of ligand-receptor interactions[J].Proc Natl Acad Sci U S A,2015,112:15862-15867
[69]Katayama R,Lovly CM,Shaw AT.Therapeutic targeting of anaplastic lymphoma kinase in lung cancer:a paradigm for precision cancer medicine[J].Clin Cancer Res,2015,21:2227-2235
[70]Murray PB,Lax I,Reshetnyak A,et al.Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK[J].Sci Signal,2015,8:ra6
[71]Gadgeel SM,Gandhi L,Riely GJ,et al.Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer(AF-002JG):results from the dose-finding portion of a phase 1/2 study[J].Lancet Oncol,2014,15:1119-1128
[72]Toyokawa G,Seto T,Takenoyama M,et al.Insights into brain metastasis in patients with ALK+lung cancer:is the brain truly a sanctuary?[J].Cancer Metastasis Rev,2015,34:797-805
[73]Gandhi L,Ou SI,Shaw AT,et al.Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer:Comparison of RECIST 1.1and RANO-HGG criteria[J].Eur J Cancer,2017,82:27-33
[74]Peters S,Camidge DR,Shaw AT,et al.Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer[J].N Engl J Med,2017,377:829-838
[75]Iuchi T,Shingyoji M,Sakaida T,et al.Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma[J].Lung Cancer,2013,82:282-287
[76]Soon YY,Leong CN,Koh WY,et al.EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant nonsmall cell lung cancer with brain metastases:a systematic review and meta-analysis[J].Radiother Oncol,2015,114:167-172
[77]Brahmer J,Reckamp KL,Baas P,et al.Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer[J].N Engl J Med,2015,373:123-135
[78]Garon EB,Rizvi NA,Hui R,et al.Pembrolizumab for the treatment of non-small-cell lung cancer[J].N Engl J Med,2015,372:2018-2028
[79]Goldberg SB,Gettinger SN,Mahajan A,et al.Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases:early analysis of a non-randomised,open-label,phase 2 trial[J].Lancet Oncol,2016,17:976-983